Target intelligence / Profile preview

Hantavirus envelope glycoprotein Gn and Gc (Gn and Gc)

Target
Gn and Gc
Molecular classification
Viral envelope glycoprotein, Class II viral fusion protein (Gc), Viral receptor ligand, Other
01

Overview

Hantavirus envelope glycoproteins Gn and Gc are membrane-anchored proteins expressed from the viral M segment as a GPC precursor that is cleaved into mature forms[4][5]. Gn and Gc assemble as heterodimers, which further organize into tetrameric spike complexes on the viral envelope, creating a lattice structure that decorates the virion surface[1][2][5]. These glycoproteins are essential for viral entry—Gn/Gc mediates host cell recognition, endocytosis, and Gc specifically mediates the fusion of the viral and endosomal membranes at acidic pH during cell entry[2][3][5]. Gc is classified as a class II fusion protein, undergoing substantial conformational changes to expose fusion peptides and enable membrane fusion[2][3][5]. The spike complexes formed by Gn/Gc are major targets of neutralizing antibodies, which can prevent infection by blocking glycoprotein function[1][5]. Beyond entry, the cytoplasmic tails of Gn and Gc play a critical role in virion assembly and budding by interacting with the viral nucleoprotein and other assembly components[3][4]. There are currently no clinically approved drugs specifically targeting Gn or Gc, but multiple investigational monoclonal antibodies and viral entry inhibitors are being explored as potential therapeutics.

Other names
GnGcGlycoprotein NGlycoprotein CG1 (Gn)G2 (Gc)
02

Mechanism of action

Neutralizing antibodies block glycoprotein function to prevent virus entry; Fusion inhibitors stabilize prefusion state or block conformational change of Gc; Small molecules or peptides may disrupt glycoprotein assembly, fusion, or receptor binding (experimental)

03

Biological functions

Mediates virus entry into host cellsDrives receptor-mediated endocytosisFacilitates fusion of viral and endosomal membranesParticipates in viral assembly and buddingForms spike complexes on viral surface
04

Disease associations

Infection
05

Safety considerations

High variability and immune escape potential complicate vaccine or antibody efficacyPotential for antibody-dependent enhancement is theoretical but not confirmedDelivery and safety of fusion-inhibitory drugs in humans remain to be established
06

Interacting drugs

No approved drugs directly target these proteins in clinical use as of 2024

2 more in the full profile.

07

Biomarkers

Antibody responses against Gn or Gc are used as serological biomarkers for hantavirus infection

Beyond the preview

Go deeper on Hantavirus envelope glycoprotein Gn and Gc (Gn and Gc).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hantavirus envelope glycoprotein Gn and Gc (Gn and Gc).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call